Renata PLC
Empagliflozin Diabetes & metabolic
Originator: Jardiance · Boehringer Ingelheim, co-marketed with Eli Lilly and Company (licensed from Boehringer Ingelheim International GmbH)
| Brand | Strength | Form |
|---|---|---|
| Diampa | 10 mg, 25 mg | — |
| Diampa | 25 mg | Tablet |
| Diampa | 10 mg | Tablet |
Linagliptin Diabetes & metabolic
Originator: Tradjenta · Boehringer Ingelheim (marketed in the US by Boehringer Ingelheim Pharmaceuticals, Inc.; co-promoted with Eli Lilly in several markets)
| Brand | Strength | Form |
|---|---|---|
| Glinta | 5 mg | Tablet |
Olaparib Cancer (oncology)
Originator: Lynparza · AstraZeneca (distributed by AstraZeneca Pharmaceuticals LP); developed and commercialised in collaboration with Merck (MSD outside the US and Canada)
| Brand | Strength | Form |
|---|---|---|
| Ovarib | 100 mg | Tablet |
Osimertinib Cancer (oncology)
Originator: Tagrisso · AstraZeneca
| Brand | Strength | Form |
|---|---|---|
| Rosimer | 80 mg tablet | — |
| Rosimer | 80 mg | Tablet |
Palbociclib Cancer (oncology)
Originator: Ibrance · Pfizer Inc. (Pfizer Laboratories Div Pfizer Inc)
| Brand | Strength | Form |
|---|---|---|
| Paltab | 125 mg tablet | — |
| Paltab | 125 mg | Tablet |
Sitagliptin Diabetes & metabolic
Originator: Januvia · Merck Sharp & Dohme (MSD), a subsidiary of Merck & Co., Inc.
| Brand | Strength | Form |
|---|---|---|
| Sitacret | 50 mg | Tablet |
Tofacitinib Immunology & rheumatology
Originator: Xeljanz / Xeljanz XR · Pfizer (initial U.S. approval 2012)
| Brand | Strength | Form |
|---|---|---|
| Jakrif | 5 mg | Tablet |
This page is an information resource for healthcare professionals, licensed importers and patients under medical care. It is not medical advice, not a prescription service, and not an offer to sell prescription medicines to the public.
Need a verified quotation?
Send us the molecule, strength, pack size, quantity and destination country. We reply with a batch-traceable quotation, certificates of analysis and shipping documentation.
We supply licensed pharmacies, hospitals, importers and distributors — not direct-to-consumer patients.
